ADV placebo

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Chronic Hepatitis B

Phase 3

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

CompletedNCT00116805

Gilead SciencesChronic Hepatitis B

Start: 2005-06-30End: 2016-01-31Updated: 2017-03-09

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

CompletedNCT00117676

Gilead SciencesChronic Hepatitis B

Start: 2005-02-28End: 2016-01-31Updated: 2017-03-07

Related Papers

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.

2024-08-0728 citations

Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection

Liver International2019-05-28151 citations

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

2019-02-2022 citations

Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.

2017-02-1217 citations

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

Gut2016-08-1762 citations

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

2012-12-101322 citations

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

2008-12-01810 citations